全身化疗联合根治性肾输尿管切除术治疗转移性上尿路尿路上皮癌的疗效
基于美国国家癌症数据库(2004-2012年)的观察性研究,纳入接受化疗联合根治性肾输尿管切除术(RNU)的398例(38.4%)和仅接受化疗的637例(61.6%)转移性上尿路尿路上皮癌患者。经逆概率处理加权(IPTW)调整后,联合RNU组3年总生存率为16.2%(95%CI 12.1-20.3),仅化疗组为6.4%(95%CI 4.1-8.7)(p<0.001);联合RNU与显著总生存获益相关(HR 0.70,95%CI 0.61-0.80;p<0.001)。作者认为,尽管存在观察性研究设计的常见偏倚,对于适合的患者,化疗联合RNU较单纯化疗显示净总生存获益。
要点
- 化疗联合RNU组3年OS为16.2%,仅化疗组为6.4%(p<0.001)。
- IPTW调整后,化疗联合RNU与显著OS获益相关(HR 0.70,95%CI 0.61-0.80)。
- 作者认为适合的mUTUC患者接受化疗联合RNU可能获得净OS获益。
核心结论
- 作者认为,尽管存在观察性研究设计的常见偏倚,对于适合的转移性上尿路尿路上皮癌患者,化疗联合根治性肾输尿管切除术较单纯化疗显示净总生存获益。
研究设计与样本
- 基于美国国家癌症数据库(2004-2012年)的观察性研究,纳入398例(38.4%)接受化疗联合根治性肾输尿管切除术和637例(61.6%)仅接受化疗的转移性上尿路尿路上皮癌患者。
主要发现
- IPTW调整的Kaplan-Meier曲线显示,化疗联合RNU组3年OS为16.2%(95%CI 12.1-20.3),仅化疗组为6.4%(95%CI 4.1-8.7)(p<0.001)。
- IPTW调整的Cox回归分析中,化疗联合RNU与显著OS获益相关(HR 0.70,95%CI 0.61-0.80;p<0.001)。
临床怎么用
- 作者认为,对于适合的转移性上尿路尿路上皮癌患者,化疗联合根治性肾输尿管切除术可能较单纯化疗带来净总生存获益。
局限性
- 原文指出存在与观察性研究设计相关的常见偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Given the growing body of evidence supporting the benefit of primary tumor control for a wide range of metastatic malignancies, we hypothesized that chemotherapy plus radical nephroureterectomy (RNU) is associated with an overall survival (OS) benefit compared to chemotherapy alone for metastatic upper tract urothelial carcinoma (mUTUC). Within the National Cancer Data Base (2004-2012), we identified 398 (38.4%) and 637 (61.6%) patients who received chemotherapy plus RNU and chemotherapy alone, respectively. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves showed that 3-yr OS was 16.2% (95% confidence interval [CI] 12.1-20.3) for chemotherapy plus RNU and 6.4% (95%CI 4.1-8.7) for chemotherapy alone (p<0.001). In IPTW-adjusted Cox regression analysis, chemotherapy plus RNU was associated with a significant OS benefit (hazard ratio 0.70, 95% CI 0.61-0.80; p<0.001). Despite the usual biases related to the observational study design, our findings show a net OS benefit for fit patients who received chemotherapy plus RNU for mUTUC relative to their counterparts treated with chemotherapy alone. PATIENT SUMMARY: We examined the role of radical nephroureterectomy in addition to systemic chemotherapy for metastatic upper tract urothelial carcinoma. We found that such treatment may be associated with an overall survival benefit compared to chemotherapy alone in fit patients.
引用
- Seisen T, Jindal T, Karabon P, et al. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol. 2016. PMID: 27912971. doi:10.1016/j.eururo.2016.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。